Votre recherche pour: Adelphi Pharma Hygiene Products
1 679 les résultats ont été trouvés
Final fill for recombinant proteins
/cms/fr/bioprocessing_recombinant_proteins_final_fill
Final fill for recombinant proteins Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepar...
Final fill for vaccines
/cms/nl/bioprocessing_vaccines_final_fill
Final fill for vaccines Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepared in an ISO...
Final fill for mAbs
/cms/fr/bioprocessing_mabs_final_fill
Final fill for mAbs Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepared in an ISO Cla...
Final fill for recombinant proteins
/cms/nl/bioprocessing_recombinant_proteins_final_fill
Final fill for recombinant proteins Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepar...
Bürkle GmbH – Le prélèvement au niveau supérieur
/cms/fr/burkle_sampling
Bürkle GmbH – Le prélèvement au niveau supérieur Votre expert en prélèvement vous aide à trouver des solutions pour les applications et les exigences les plus diverses. Optimisez vos prélèvements grâce à nos solutions. Lors du prélèvement d’échant...
Upstream processing for mAbs
/cms/fr/bioprocessing_mabs_upstream_processing
Upstream processing for mAbs Developing and manufacturing mAbs has moved away from a dependency on raw materials of animal origin. Our biochemical components and supplements are animal component-free to meet the needs of these applications. Produc...
Upstream processing for cell therapy
/cms/fr/bioprocessing_cell_therapy_upstream_processing
Upstream processing for cell therapy Compared to production volumes associated with other biologics (e.g. mAbs: 2000L to 10000L) cell therapy production volumes are more commonly between 1L to 10L. Even the quality parameters are different. Instea...
Solutions to manage complexity in global single-use supply chain for vaccines manufacturing
/cms/nl/solutions_to_manage_vaccines
Solutions to manage complexity in global single-use supply chain for vaccines manufacturing Webinar On demand Replay Single-use systems have been proven to enable a more flexible cost-effective approach to manufacturing monoclonal antibodies (mAbs...
Final fill for gene therapy
/cms/fr/bioprocessing_gene_therapy_final_fill
Final fill for gene therapy To meet these requirements products must be prepared in an ISO Class 5 environment and meet USP71 USP85 and USP758 requirements to be sterile pyrogen-free and particulate-free. They must also be validated for use in sto...
Assays for final fill
/cms/nl/final_fill_assay
Assays for final fill Control is influenced by aseptic procedures followed in the production environment and is adhered to by employee training gowning cleaning and environmental control. Process validation steps are followed to ensure an acceptab...
Avantor Services Cell and Gene Therapy Success Sto
/m-be.vwr.com/fr_BE/images/Avantor_Services_Cell_and_Gene_Therapy_Success_Sto.pdf
Success story Avantor accelerates Cell and Gene Therapy (C>) production Avantor Services Lab and production services CHALLENGE A global pharmaceutical company set an ambitious strategic goal of transitioning from Cell and Gene Therapy (C>) con...
Avantor Services Cell and Gene Therapy Success Sto
/m-be.vwr.com/nl_BE/images/Avantor_Services_Cell_and_Gene_Therapy_Success_Sto.pdf
Success story Avantor accelerates Cell and Gene Therapy (C>) production Avantor Services Lab and production services CHALLENGE A global pharmaceutical company set an ambitious strategic goal of transitioning from Cell and Gene Therapy (C>) con...
Upstream processing for microbial-based recombinant proteins
/cms/nl/bioprocessing_recombinant_proteins_upstream_processing
Upstream processing for microbial-based recombinant proteins Using microbial fermentation for the development and manufacture of recombinant proteins keeps on showing advantages e.g for the expression of proteins that do not require post-translati...
Upstream processing for vaccines
/cms/fr/bioprocessing_vaccines_upstream_processing
Upstream processing for vaccines Optimal production of vaccines is achieved in mammalian expression and insect systems using cell lines that are anchorage-dependent or suspension enabled. For most vaccines optimal production is achieved in mammali...
Upstream processing for vaccines
/cms/nl/bioprocessing_vaccines_upstream_processing
Upstream processing for vaccines Optimal production of vaccines is achieved in mammalian expression and insect systems using cell lines that are anchorage-dependent or suspension enabled. For most vaccines optimal production is achieved in mammali...
Final fill for vaccines
/cms/fr/bioprocessing_vaccines_final_fill
Final fill for vaccines Progressing from the drug substance to the final injectable drug product requires final packaging vials and stoppers that meet a number of quality requirements. To meet these requirements products must be prepared in an ISO...
337 - 352 of 1 679